Helicobacter pylori
Conditions
Interventions
Keverprazan HydrochlorideTablets group:Amoxicillin 1000mg, twice a day + Levofloxacin Tablets 0.5g, once a day + Keverprazan Hydrochloride 20mg, twice a day + Colloidal Pectin Bismuth 200mg, twice a d
Esomeprazole group:Amoxicillin 1000mg, twice a day + Levofloxacin Tablets 0.5g, once a day + Esomeprazole 20mg, twice a day + Colloidal Bismuth Subcitrate 200mg, twice a day
Sponsors
The Air Force Hospital of Northern Theater PLA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with Hp infection who have been eradicated for the first time; (2) Age: 18 to 70 years old, gender not limited; (3) Women are required to use medically feasible contraceptive methods during the trial period and within 30 days after the trial ends.
Exclusion criteria
Exclusion criteria: (1) Patients with contraindications to the investigational drug or those allergic to the investigational drug; (2) Severe organ damage and complications (such as liver cirrhosis, uremia, etc.), severe or unstable heart, lung or endocrine diseases; (3) Continuous use of anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times per week one month before screening); (4) Pregnant and lactating women; (5) Has undergone upper gastrointestinal tract surgery; (6) Suffering from Barrett's esophagus or highly atypical hyperplasia, with symptoms of dysphagia; (7) There is evidence of bleeding or iron deficiency anemia; (8) Have a history of malignant tumors; (9) There is a history of drug or alcohol abuse within the past year; (10) Systemic application of glucocorticoids, non-steroidal anti-inflammatory drugs, anticoagulants, and platelet aggregation inhibitors (except for aspirin =100 mg/d); (11) Those with mental disorders; (12) Has undergone other clinical trials within the past three months; (13) Refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate;Clinical symptom improvement status; | — |
Countries
People's Republic of China
Contacts
Public ContactShao Lichun
The Air Force Hospital of Northern Theater PLA
Outcome results
None listed